Aspirin and antibiotics could relieve major depression | Inquirer Technology

Anti-inflammatory agents like aspirin, antibiotics could relieve symptoms of major depression

/ 05:35 PM October 29, 2019

Woman taking pills AFP Relaxnews

Taking anti-inflammatory agents such as aspirin could help to reduce the symptoms of major depression, according to new research. Image: Istock.com/diego_cervo via AFP Relaxnews

New Chinese research has found that taking anti-inflammatory agents such as aspirin, paracetamol, statins and antibiotics could help to reduce the symptoms of major depression.

A team from Huazhong University of Science and Technology analyzed 30 existing studies which included a total of 1,610 people, to investigate the efficacy and safety of taking anti-inflammatory agents as a treatment for major depressive disorder, either alone or combined with antidepressants, in comparison to taking a placebo.

Article continues after this advertisement

Anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAIDs), omega-3 fatty acids, cytokine inhibitors (drugs that curb production of inflammatory chemicals), statins, steroids, antibiotics (minocyclines), modafinil (a drug used to treat sleep disorders), and N-acetyl cysteine (known as NAC and taken as an antioxidant supplement and to loosen the excess phlegm of cystic fibrosis and COPD).

FEATURED STORIES

The findings, published in the Journal of Neurology, Neurosurgery & Psychiatry, showed that anti-inflammatory agents safely and effectively curbed the symptoms of major depression, and were 52% more effective at reducing symptom severity overall, and 79% more effective in eliminating symptoms than a placebo.

The effect of anti-inflammatory agents was even stronger when they were added to a standard antidepressant treatment.

Article continues after this advertisement

When the researchers looked at which of the agents provided the most benefits, they found that NSAIDs, omega 3 fatty acids, statins, and minocyclines were the most effective at reducing major depressive symptoms compared with taking a placebo.

Article continues after this advertisement

However, anti-inflammatory agents didn’t appear to improve patients’ quality of life. The researchers explained that this might be due to only a small number of studies investigating this aspect, or because major depressive disorder is a chronic disease which requires long-term treatment and “it is difficult to obtain improvement in quality of life measures in several weeks.”

Article continues after this advertisement

No major side effects were observed from taking anti-inflammatory agents, although those who took statins and NACs did experience some gut symptoms. The team added that as most trials lasted only four to 12 weeks, it was not possible to track possible long-term side effects.

Although they note that more research is needed, the team concluded, “The results of this systematic review suggest that anti-inflammatory agents play an antidepressant role in patients with major depressive disorder and are reasonably safe.” CL/JB

Article continues after this advertisement

RELATED STORIES:

Digital technology use not linked to risk of depression in teens — study

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

A mother’s exposure to certain chemicals during early pregnancy could lower their child’s IQ

TOPICS: antibiotics, aspirin, Depression, paracetamol, placebo
TAGS: antibiotics, aspirin, Depression, paracetamol, placebo

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.